Trial Profile

A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec Docetaxel in Patients With Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary)
Indications Solid tumours
Focus Adverse reactions; Pharmacokinetics
Acronyms NAPOLY
Sponsors Cristal Therapeutics

Most Recent Events

04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
17 May 2019 Results published in the Media Release
17 May 2019 According to a Cristal Therapeutics media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting. Florence Atrafi is one of the clinical investigators.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com